Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients

Authors: Yu-Chi Chang, Bang-Gee Hsu, Hung-Hsiang Liou, Chung-Jen Lee, Ji-Hung Wang

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

Sclerostin is known to be a canonical Wnt/β-catenin signaling pathway inhibitor, while the Wnt/β-catenin signaling pathway is proposed to be involved in the development of arterial stiffness. This study aims to investigate the relationship between serum sclerostin levels and carotid–femoral pulse wave velocity (cfPWV) among hypertensive patients.

Methods

Fasting blood samples were obtained from 105 hypertensive patients. Patients with cfPWV values of > 10 m/s were classified in the high arterial stiffness group, whereas those with cfPWV values of ≤10 m/s were assigned to the low arterial stiffness group. Serum sclerostin and Dickkopf-1 (DKK1) levels were quantified using commercially available enzyme-linked immunosorbent assays.

Results

Thirty-six hypertensive patients (34.3%) who belonged to the high arterial stiffness group were generally older (p < 0.001), presented with lower estimated glomerular filtration rates (eGFR, p = 0.014), higher incidence of diabetes mellitus (p = 0.030), average systolic blood pressures (SBP, p = 0.013), pulse pressure (p = 0.026), serum creatinine levels (p = 0.013), intact parathyroid hormone levels (iPTH, p = 0.003), and sclerostin levels (p < 0.001) than their counterparts in the low arterial stiffness group. A multivariable logistic regression analysis identified sclerostin as an independent predictor of arterial stiffness in hypertensive patients (odds ratio, 1.042; 95% confidence interval (CI), 1.017–1.068; p = 0.001). Multivariable forward stepwise linear regression analysis also showed that serum sclerostin level (β = 0.255, adjusted R2 change: 0.146, p = 0.003) was positively associated with cfPWV values in patients with hypertension.

Conclusions

In this study, serum sclerostin level, but not DKK1, is found to be positively correlated with cfPWV values and is identified as an independent predictor of arterial stiffness in hypertensive patients after adjusting for significant confounders.
Literature
1.
go back to reference O'Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. Clin Chim Acta. 2017;465:131–43.CrossRef O'Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. Clin Chim Acta. 2017;465:131–43.CrossRef
2.
go back to reference Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–27.CrossRef Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–27.CrossRef
3.
go back to reference Palatini P, Casiglia E, Gąsowski J, Głuszek J, Jankowski P, Narkiewicz K, Saladini F, Stolarz-Skrzypek K, Tikhonoff V, Van Bortel L, et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag. 2011;7:725–39.CrossRef Palatini P, Casiglia E, Gąsowski J, Głuszek J, Jankowski P, Narkiewicz K, Saladini F, Stolarz-Skrzypek K, Tikhonoff V, Van Bortel L, et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag. 2011;7:725–39.CrossRef
4.
go back to reference Kubozono T, Ohishi M. Prognostic significance of regional arterial stiffness for stroke in hypertension. Pulse. 2015;3(2):98–105.CrossRef Kubozono T, Ohishi M. Prognostic significance of regional arterial stiffness for stroke in hypertension. Pulse. 2015;3(2):98–105.CrossRef
5.
go back to reference Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: a problem with cause and consequence. Circ Res. 2016;118(3):379–81.CrossRef Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: a problem with cause and consequence. Circ Res. 2016;118(3):379–81.CrossRef
6.
go back to reference Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vasc Pharmacol. 2016;77:1–7.CrossRef Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vasc Pharmacol. 2016;77:1–7.CrossRef
7.
8.
go back to reference Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into arterial structure and physiology (ARTERY) society. Atherosclerosis. 2015;241(2):507–32.CrossRef Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into arterial structure and physiology (ARTERY) society. Atherosclerosis. 2015;241(2):507–32.CrossRef
9.
go back to reference AlGhatrif M, Lakatta EG. The conundrum of arterial stiffness, elevated blood pressure. and aging Curr Hypertens Rep. 2015;17(2):12.CrossRef AlGhatrif M, Lakatta EG. The conundrum of arterial stiffness, elevated blood pressure. and aging Curr Hypertens Rep. 2015;17(2):12.CrossRef
10.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31((10)):1925–38.CrossRef Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31((10)):1925–38.CrossRef
11.
go back to reference Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014;6(2):48–57.CrossRef Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014;6(2):48–57.CrossRef
12.
go back to reference Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J, He W. WNT/β-catenin signalling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res. 2016;345(2):206–17.CrossRef Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J, He W. WNT/β-catenin signalling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res. 2016;345(2):206–17.CrossRef
13.
go back to reference Ma S, Yao S, Tian H, Jiao P, Yang N, Zhu P, Qin S. Pigment epithelium-derived factor alleviates endothelial injury by inhibiting Wnt/β-catenin pathway. Lipids Health Dis. 2017;16(1):31.CrossRef Ma S, Yao S, Tian H, Jiao P, Yang N, Zhu P, Qin S. Pigment epithelium-derived factor alleviates endothelial injury by inhibiting Wnt/β-catenin pathway. Lipids Health Dis. 2017;16(1):31.CrossRef
14.
go back to reference Zhou L, Liu Y. Wnt/β-catenin signalling and renin-angiotensin system in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(2):100–6.CrossRef Zhou L, Liu Y. Wnt/β-catenin signalling and renin-angiotensin system in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(2):100–6.CrossRef
15.
go back to reference Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33(5):747–83.CrossRef Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33(5):747–83.CrossRef
16.
go back to reference Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E. SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2015;438:401–14.CrossRef Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E. SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2015;438:401–14.CrossRef
17.
go back to reference Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98(8):3221–8.CrossRef Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98(8):3221–8.CrossRef
18.
go back to reference Hortells L, Sosa C, Guillén N, Lucea S, Millán Á, Sorribas V. Identifying early pathogenic events during vascular calcification in uremic rats. Kidney Int. 2017;92(6):1384–94.CrossRef Hortells L, Sosa C, Guillén N, Lucea S, Millán Á, Sorribas V. Identifying early pathogenic events during vascular calcification in uremic rats. Kidney Int. 2017;92(6):1384–94.CrossRef
19.
go back to reference Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRef Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRef
20.
go back to reference Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC. Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients-a cross-sectional study. Medicine. 2016;95(15):e3300.CrossRef Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC. Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients-a cross-sectional study. Medicine. 2016;95(15):e3300.CrossRef
21.
go back to reference Tsai JP, Wang JH, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum leptin levels with central arterial stiffness in coronary artery disease patients. BMC Cardiovasc Disord. 2016;16:80.CrossRef Tsai JP, Wang JH, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum leptin levels with central arterial stiffness in coronary artery disease patients. BMC Cardiovasc Disord. 2016;16:80.CrossRef
22.
go back to reference Wang JH, Lee CJ, Yang CF, Chen YC, Hsu BG. Serum resistin as an independent marker of aortic stiffness in patients with coronary artery disease. PLoS One. 2017;12(8):e0183123.CrossRef Wang JH, Lee CJ, Yang CF, Chen YC, Hsu BG. Serum resistin as an independent marker of aortic stiffness in patients with coronary artery disease. PLoS One. 2017;12(8):e0183123.CrossRef
23.
go back to reference Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65(2):252–6.CrossRef Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65(2):252–6.CrossRef
24.
go back to reference Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CD. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn study. Hypertension. 2004;43(2):176–81.CrossRef Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Westerhof N, Stehouwer CD. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn study. Hypertension. 2004;43(2):176–81.CrossRef
25.
go back to reference Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6):1328–36.CrossRef Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6):1328–36.CrossRef
26.
go back to reference Cheng YB, Li LH, Guo QH, Li FK, Huang QF, Sheng CS, Wang JG, Staessen JA, Li Y. Independent effects of blood pressure and parathyroid hormone on aortic pulse wave velocity in untreated Chinese patients. J Hypertens. 2017;35(9):1841–8.CrossRef Cheng YB, Li LH, Guo QH, Li FK, Huang QF, Sheng CS, Wang JG, Staessen JA, Li Y. Independent effects of blood pressure and parathyroid hormone on aortic pulse wave velocity in untreated Chinese patients. J Hypertens. 2017;35(9):1841–8.CrossRef
27.
go back to reference Woodard T, Sigurdsson S, Gotal JD, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Gudnason V, Harris TB, Launer LJ, et al. Mediation analysis of aortic stiffness and renal microvascular function. J Am Soc Nephrol. 2015;26(5):1181–7.CrossRef Woodard T, Sigurdsson S, Gotal JD, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Gudnason V, Harris TB, Launer LJ, et al. Mediation analysis of aortic stiffness and renal microvascular function. J Am Soc Nephrol. 2015;26(5):1181–7.CrossRef
28.
go back to reference Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens. 2010;23(3):282–9.CrossRef Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens. 2010;23(3):282–9.CrossRef
29.
go back to reference Garnier AS, Briet M. Arterial stiffness and chronic kidney disease. Pulse. 2016;3(3–4):229–41.CrossRef Garnier AS, Briet M. Arterial stiffness and chronic kidney disease. Pulse. 2016;3(3–4):229–41.CrossRef
30.
go back to reference Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4(4):251–68.CrossRef Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4(4):251–68.CrossRef
31.
go back to reference Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res. 2013;54(12):3227–43.CrossRef Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res. 2013;54(12):3227–43.CrossRef
32.
go back to reference Wang F, Ye P, Luo L, Xiao W, Qi L, Bian S, Wu H, Sheng L, Xiao T, Xu R. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Investig. 2011;41(9):929–36.CrossRef Wang F, Ye P, Luo L, Xiao W, Qi L, Bian S, Wu H, Sheng L, Xiao T, Xu R. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Investig. 2011;41(9):929–36.CrossRef
33.
go back to reference Wang X, Du Y, Fan L, Ye P, Yuan Y, Lu X, Wang F, Zeng Q. Relationships between HDL-C, hs-CRP, with central arterial stiffness in apparently healthy people undergoing a general health examination. PLoS One. 2013;8(12):e81778.CrossRef Wang X, Du Y, Fan L, Ye P, Yuan Y, Lu X, Wang F, Zeng Q. Relationships between HDL-C, hs-CRP, with central arterial stiffness in apparently healthy people undergoing a general health examination. PLoS One. 2013;8(12):e81778.CrossRef
34.
go back to reference Peiris AN, Youssef D, Grant WB. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? South Med J. 2012;105(1):36–42.CrossRef Peiris AN, Youssef D, Grant WB. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? South Med J. 2012;105(1):36–42.CrossRef
35.
go back to reference Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, Johansson L, Ingelsson E, Sundström J, Lind L, Arnlöv J. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34(7):1567–73.CrossRef Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, Johansson L, Ingelsson E, Sundström J, Lind L, Arnlöv J. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2014;34(7):1567–73.CrossRef
36.
go back to reference Tölle M, Reshetnik A, Schuchardt M, Höhne M, van der Giet M. Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy. Eur J Clin Invest. 2015;45(9):976–85.CrossRef Tölle M, Reshetnik A, Schuchardt M, Höhne M, van der Giet M. Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy. Eur J Clin Invest. 2015;45(9):976–85.CrossRef
37.
go back to reference Pikilidou M, Yavropoulou M, Antoniou M, Yovos J. The contribution of osteoprogenitor cells to arterial stiffness and hypertension. J Vasc Res. 2015;52(1):32–40.CrossRef Pikilidou M, Yavropoulou M, Antoniou M, Yovos J. The contribution of osteoprogenitor cells to arterial stiffness and hypertension. J Vasc Res. 2015;52(1):32–40.CrossRef
38.
go back to reference Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6(5):e19595.CrossRef Zhu D, Mackenzie NC, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6(5):e19595.CrossRef
39.
go back to reference Sehgel NL, Vatner SF, Meininger GA. “Smooth muscle cell stiffness syndrome”-revisiting the structural basis of arterial stiffness. Front Physiol. 2015;6:335.CrossRef Sehgel NL, Vatner SF, Meininger GA. “Smooth muscle cell stiffness syndrome”-revisiting the structural basis of arterial stiffness. Front Physiol. 2015;6:335.CrossRef
40.
go back to reference Kirkpantur A, Balci M, Turkvatan A, Afsar B. Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J. 2015;8(6):737–43.CrossRef Kirkpantur A, Balci M, Turkvatan A, Afsar B. Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J. 2015;8(6):737–43.CrossRef
41.
go back to reference Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–56.CrossRef Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–56.CrossRef
42.
go back to reference Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology. 2017;22(4):286–92.CrossRef Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology. 2017;22(4):286–92.CrossRef
43.
go back to reference Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA. European Uremic Toxin (EUTox) Work Group. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. 2014;10(6):463–70.CrossRef Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA. European Uremic Toxin (EUTox) Work Group. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. 2014;10(6):463–70.CrossRef
44.
go back to reference Jin S, Zhu M, Yan J, Fang Y, Lu R, Zhang W, Zhang Q, Lu J, Qi C, Shao X, et al. Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomark Med. 2016;10(7):689–99.CrossRef Jin S, Zhu M, Yan J, Fang Y, Lu R, Zhang W, Zhang Q, Lu J, Qi C, Shao X, et al. Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomark Med. 2016;10(7):689–99.CrossRef
45.
go back to reference Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signaling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56(1):42–7.CrossRef Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signaling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56(1):42–7.CrossRef
46.
go back to reference Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R, Muñoz-Torres M. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013;36(6):1667–74.CrossRef Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R, Muñoz-Torres M. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013;36(6):1667–74.CrossRef
47.
go back to reference Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. 2017;100:80–6.CrossRef Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. 2017;100:80–6.CrossRef
48.
go back to reference Gaudio A, Fiore V, Rapisarda R, Sidoti MH, Xourafa A, Catalano A, Tringali G, Zanoli L, Signorelli SS, Fiore CE. Sclerostin is a possible candidate marker of arterial stiffness: results from a cohort study in Catania. Mol Med Rep. 2017;15(5):3420–4.CrossRef Gaudio A, Fiore V, Rapisarda R, Sidoti MH, Xourafa A, Catalano A, Tringali G, Zanoli L, Signorelli SS, Fiore CE. Sclerostin is a possible candidate marker of arterial stiffness: results from a cohort study in Catania. Mol Med Rep. 2017;15(5):3420–4.CrossRef
Metadata
Title
Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients
Authors
Yu-Chi Chang
Bang-Gee Hsu
Hung-Hsiang Liou
Chung-Jen Lee
Ji-Hung Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0955-5

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue